Document is current

Article History

Received: 17 December 2024

Accepted: 26 March 2025

First Online: 21 April 2025

Declarations

:

: This study was conducted in accordance with the 1964 Declaration of Helsinki and its subsequent amendments. The version of NeuroBlu used contained de-identified data from the MindLinc EHR. For the MindLinc EHR, institutional review board (IRB) approval for this study was not required because MindLinc data are anonymised and thus exempt from Health Insurance Portability and Accountability Act requirements. The NeuroBlu Database platform has received a waiver of informed consent prior to study conduct from the WCG Institutional Review Board (Ref: The Holmusk Real-World Evidence Parent Protocol; IRB registration number 1–1470336-1; Protocol ID HolmuskRWE_1.0).

: Not applicable.

: At the time of this study, KG, and YW report employment with and equity ownership in KKT Technologies Pte. Ltd. or its subsidiaries. RP, MR, ZL and LW are previous employees of Holmusk Technologies Inc. RP has received grant funding from the National Institute for Health and Care Research (NIHR301690), the Medical Research Council (MR/S003118/1). RP has been a Scientific Advisory Board member for Boehringer Ingelheim, has received grant funding from Janssen, and has received consulting fees from Holmusk, Akrivia Health, Columbia Data Analytics, Clinilabs, Social Finance, Boehringer Ingelheim, Bristol Myers Squibb, Teva and Otsuka. CC has been a consultant and/or advisor to or has received honoraria from: AbbVie, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Bristol-Meyers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Eli Lilly, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, MedLink, Merck, Mindpax, Mitsubishi Tanabe Pharma, Maplight, Mylan, Neumora Therapeutics, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Saladax, Sanofi, Seqirus, Servier, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Terran, Tolmar, Vertex, Viatris and Xenon Pharmaceuticals. He provided expert testimony for Janssen, Lundbeck and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, IntraCellular Therapies, Relmada, Reviva, Rovi. He has received grant support from Boehringer-Ingelheim, Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Medlink, Mindpax, Quantic, Terran.